Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of Low-Dose Cyclophosphamide, Tumor Associated Peptide Antigen-Pulsed Dendritic Cell Therapy and Imiquimod, in Patients With Progressive and/or Refractory Solid Malignancies

NCT02224599 is registered in ClinicalTrials.gov with Kiromic BioPharma Inc. as lead sponsor.

NCT NCT02224599
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02224599 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of Low-Dose Cyclophosphamide, Tumor Associated Peptide Antigen-Pulsed Dendritic Cell Therapy and Imiquimod, in Patients With Progressive and/or Refractory Solid Malignancies
Lead sponsor
Kiromic BioPharma Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
July 28, 2017
Completion date
August 30, 2018
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, progressive solid malignancies, refractory solid malignancies